Heparin fractions and derivatives.
Thromboembolic disease continues to plague mankind because it is often detected too late for effective management, because modern therapeutic measures are often inefficiently managed, and because new therapeutic agents and available laboratory tests are ignored. New investigations that continue to be reported in Seminars in Thrombosis and Hemostasis and other journals deserve greater recognition and appreciation. Physicians and other scientists have reached a point at which antithrombotic and hemorrhagic effects of therapeutic anticoagulants can become dissociated if they effectively work together at the many interfaces for research and development among them to harvest the yield of basic research for practical clinical application.
D000991:Antithrombins / Q000378:metabolism; D001780:Blood Coagulation Tests; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D005344:Fibrinopeptide A / Q000378:metabolism; D006493:Heparin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D009844:Oligosaccharides / Q000627:therapeutic use*; D011516:Prothrombin / Q000037:antagonists & inhibitors; D011655:Pulmonary Embolism / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy
D000991:Antithrombins; D009844:Oligosaccharides; D005344:Fibrinopeptide A; D011516:Prothrombin; D005170:Factor X; C025337:Factor IIa; D006493:Heparin; D015951:Factor Xa